Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Kaihong Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1164-8115; OpenAlex author ID A5008965354. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 4 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper

Papers 26

  1. Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Co-author DOI 10.1039/d5nr90172c↗
  2. Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer. Co-author DOI 10.1002/jev2.12484↗
  3. Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.216784↗
  4. Glycolysis and tumor progression promoted by the m6A writer VIRMA via m6A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216840↗
  5. Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02880-8↗
  6. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Co-author DOI 10.1016/j.phrs.2022.106555↗
  7. Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1186/s13014-023-02273-w↗
  8. TIMP1 derived from pancreatic cancer cells stimulates Schwann cells and promotes the occurrence of perineural invasion. Co-author DOI 10.1016/j.canlet.2022.215863↗
  9. Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia… Co-author DOI 10.1039/d2bm01039a↗
  10. A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194722↗
  11. GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network. Co-author DOI 10.7150/jca.72161↗
  12. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.bcp.2020.114085↗
  13. Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer. Last author DOI 10.21037/tcr-21-980↗
  14. Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer. Last author DOI 10.3389/fgene.2021.632803↗
  15. Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. Co-author DOI 10.1002/cam4.2930↗
  16. Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Last author DOI 10.1007/s10637-019-00791-7↗
  17. Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Co-author DOI 10.1039/c9nr04976b↗
  18. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8. Last author DOI 10.1002/cam4.1824↗
  19. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Co-author DOI 10.1002/ijc.31248↗
  20. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Co-author DOI 10.7150/thno.24281↗
  21. New developments in the early diagnosis of pancreatic cancer. Last author DOI 10.1080/17474124.2017.1271323↗
  22. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Co-author DOI 10.1111/cas.13267↗
  23. Pancreatic Cancer Epidemiology, Detection, and Management. Last author DOI 10.1155/2016/8962321↗
  24. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy. Last author DOI 10.1166/jbn.2016.2269↗
  25. Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China. Last author DOI 10.3747/co.22.2150↗
  26. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic can… Last author DOI 10.1016/j.nano.2013.08.007↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yaqing Li · 19 shared papers, 2016–2025 · strength 2.57
  2. Guoda Lian · 20 shared papers, 2016–2025 · strength 2.51
  3. Jinmao Zou · 12 shared papers, 2020–2025 · strength 2.00
  4. Shaojie Chen · 15 shared papers, 2016–2024 · strength 1.90
  5. Yinting Chen · 15 shared papers, 2014–2025 · strength 1.54
  6. Shangxiang Chen · 9 shared papers, 2020–2025 · strength 1.32
  7. Kege Yang · 10 shared papers, 2016–2024 · strength 1.23
  8. Shurui Zhou · 7 shared papers, 2022–2024 · strength 1.20
  9. Jiajia Li · 8 shared papers, 2016–2024 · strength 1.02
  10. Linjuan Zeng · 11 shared papers, 2014–2025 · strength 0.94
  11. Yue Zhao · 5 shared papers, 2022–2024 · strength 0.94
  12. Ziyi Zhong · 5 shared papers, 2022–2024 · strength 0.93
  13. Hanming Yao · 4 shared papers, 2022–2024 · strength 0.69
  14. Shaojie Chen · 4 shared papers, 2020–2025 · strength 0.68
  15. Yunlong Li · 3 shared papers, 2022–2024 · strength 0.54
  16. Yuzhou Huang · 3 shared papers, 2022–2024 · strength 0.51
  17. Qiubo Zhang · 6 shared papers, 2014–2020 · strength 0.46
  18. Jiajia Li · 3 shared papers, 2017–2024 · strength 0.41
  19. Jiajia Li · 3 shared papers, 2016–2025 · strength 0.40
  20. Fengjiao Li · 2 shared papers, 2022–2023 · strength 0.29
  21. Chumei Huang · 4 shared papers, 2017–2018 · strength 0.29
  22. Zhenfeng Tian · 2 shared papers, 2021–2022 · strength 0.28
  23. Ying Tan · 2 shared papers, 2020–2021 · strength 0.23
  24. Yuzhou Huang · 1 shared paper, 2024 · strength 0.20
  25. Yanji Luo · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.